SY-008
/ Eli Lilly, Yabao Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 18, 2022
Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=30 | Completed | Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Recruiting ➔ Completed | Trial primary completion date: Jun 2021 ➔ Dec 2021
Trial completion • Trial primary completion date • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus
May 18, 2021
Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus
April 14, 2020
Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=30; Not yet recruiting; Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Clinical • New P1 trial • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 3
Of
3
Go to page
1